Market Place
Sourcing Support
Iterion Announces First Patient Dosed in Phase 1b/2a Trial of Tegavivint
20 Feb 2024 //
PR NEWSWIRE
Iterion Therapeutics Announces the Initiation of a Ph 1 Trial for Tegavivint
16 May 2023 //
PR NEWSWIRE
Iterion Tx Announces Results from PI Dose Escalation Study of Tegavivint
01 Jun 2022 //
PRNEWSWIRE
Iterion Tx to Present 3 Posters Involving Research into Tegavivint at AACR
08 Apr 2022 //
PRNEWSWIRE
Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
10 Nov 2021 //
CLINICALTRIALSARENA
Iterion Announces Initiation of Ph1/2 Clinical Trial to Study Tegavivint
09 Nov 2021 //
PRNEWSWIRE
Iterion begins Phase I/II trial to assess tegavivint in paediatric cancers
09 Nov 2021 //
CLINICALTRIALSARENA
Iterion begins phase 1 trial of tegavivint to treat AML
21 Oct 2021 //
PHARMABIZ
Iterion Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint
19 Oct 2021 //
PRNEWSWIRE
Iterion Confirms Safety of Tegavivint Following Completion of Enrollmen
13 Apr 2021 //
PRNEWSWIRE
Iterion Secures $17 M to Advance Development of Tegavivint in Multiple
16 Feb 2021 //
PRNEWSWIRE
Apollomics, and Iterion Announce Exclusive Collaboration and License Agreement
10 Feb 2021 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.